Abbott has announced findings from the FreeDM2 randomized controlled trial, which demonstrates that its FreeStyle Libre continuous glucose monitoring technology enables people with Type 2 diabetes who are on basal insulin to achieve better glucose management compared to those relying on traditional fingerstick methods.
In other words, Abbott's FreeStyle Libre offers a more dynamic and informative approach to daily diabetes care, replacing intermittent and often inconvenient fingerprick tests with real-time, continuous glucose readings that empower individuals to make immediate, informed decisions about their diet, insulin dosage, and physical activity. The study's results show a 0.6 percent greater reduction in HbA1c and an additional two and a half hours per day spent in a healthy glucose range.
Abbott's FreeStyle Libre technology addresses a significant gap in care, as real-world data indicates that a large majority of people on basal insulin are not currently meeting their glucose targets.
Tech-Enabled Diabetes Management Studies
Abbott Highlights Efficacy of FreeStyle Libre Technology
Trend Themes
-
Continuous Glucose Monitoring Adoption — Widespread replacement of fingerstick testing with wearable sensors could enable continuous patient monitoring and personalized glycemic analytics that reshape chronic disease management.
-
Real-time Data-driven Care — Immediate glucose telemetry creates opportunities for adaptive treatment algorithms and clinician dashboards that predict glycemic excursions before they occur.
-
Basal Insulin Optimization Through Analytics — Linking basal insulin regimens to longitudinal CGM data may produce algorithmic dosing adjustments and new performance metrics for insulin adequacy.
Industry Implications
-
Medical Devices — Integration of sensor platforms with interoperable hardware could lead to modular devices combining monitoring, dosing, and diagnostics in a single ecosystem.
-
Digital Health Platforms — Cloud-based analysis of continuous glucose data may support subscription services offering predictive analytics and population-level outcome tracking.
-
Insulin Delivery Systems — Closed-loop and smart-pen technologies paired with CGM inputs have the potential to transform basal insulin delivery into automated, feedback-controlled therapies.